ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 914,65
-0,88%
Dow Jones
38 225,66
0,85%
DAX
17 896,50
-0,14%
Brent Oil
83,63
0,11%
Bitcoin
59 380,69
1,96%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Chemomab Therapeutics Ltd (CMMB)

  7. Chemomab Therapeutics Ltd (CMMB) Actualités

CMMB

Chemomab Therapeutics (CMMB)

Chemomab Therapeutics Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:CMMB
DateHeureSourceTitreSymboleSociété
02/05/202413h00GlobeNewswire Inc.Chemomab Therapeutics to Present at 2024 Aegis Virtual ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
24/04/202413h00GlobeNewswire Inc.Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
18/04/202413h00GlobeNewswire Inc.Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic SclerosisNASDAQ:CMMBChemomab Therapeutics Ltd
02/04/202413h00GlobeNewswire Inc.Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024NASDAQ:CMMBChemomab Therapeutics Ltd
25/03/202412h06GlobeNewswire Inc.Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
07/03/202413h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CMMBChemomab Therapeutics Ltd
07/03/202413h00PR Newswire (US)Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
05/03/202413h00PR Newswire (US)Chemomab Therapeutics to Participate in Leerink Global BioPharma ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
20/02/202415h20AllPennyStocks.comBiotech Shares Massively Bid Up Before Opening BellNASDAQ:CMMBChemomab Therapeutics Ltd
20/02/202413h00PR Newswire (US)Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory DiseasesNASDAQ:CMMBChemomab Therapeutics Ltd
14/02/202413h00PR Newswire (US)Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
05/02/202413h00PR Newswire (US)Chemomab Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:CMMBChemomab Therapeutics Ltd
30/01/202413h00PR Newswire (US)Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
03/01/202413h00PR Newswire (US)Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024NASDAQ:CMMBChemomab Therapeutics Ltd
16/11/202313h00PR Newswire (US)Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic SclerosisNASDAQ:CMMBChemomab Therapeutics Ltd
15/11/202322h35Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:CMMBChemomab Therapeutics Ltd
15/11/202313h00PR Newswire (US)Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
13/11/202314h00PR Newswire (US)Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023NASDAQ:CMMBChemomab Therapeutics Ltd
09/11/202314h00PR Newswire (US)Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
06/11/202322h15PR Newswire (US)Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price RequirementNASDAQ:CMMBChemomab Therapeutics Ltd
06/11/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CMMBChemomab Therapeutics Ltd
30/10/202313h33Edgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:CMMBChemomab Therapeutics Ltd
30/10/202312h00PR Newswire (US)Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
26/10/202313h00PR Newswire (US)Chemomab Therapeutics to Present at Upcoming Scientific ConferencesNASDAQ:CMMBChemomab Therapeutics Ltd
16/10/202322h25Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:CMMBChemomab Therapeutics Ltd
28/09/202313h00PR Newswire (US)Chemomab Therapeutics to Present Its CM-101 Clinical Program in Primary Sclerosing Cholangitis at 2023 Roth MKM Healthcare Opportunities ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
29/08/202313h00PR Newswire (US)Chemomab Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CMMBChemomab Therapeutics Ltd
14/08/202314h00PR Newswire (US)Chemomab Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:CMMBChemomab Therapeutics Ltd
05/07/202323h48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CMMBChemomab Therapeutics Ltd
28/06/202313h00PR Newswire (US)Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing CholangitisNASDAQ:CMMBChemomab Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CMMB

Dernières Valeurs Consultées

EU
DG
Vinci
USI
USTECH100
US Tech 100
FTSE
UKX
FTSE 100
EU
EN
Bouygues
NASDAQ
AMZN
Amazon.com
NYSE
DIS
Walt Disney
NASDAQ
NVDA
NVIDIA
EU
LR
Legrand
NASDAQ
MSFT
Microsoft
COIN
BTCUSD
Bitcoin
NYSE
KO
Coca Cola
EU
BNP
BNP Paribas
EU
AF
Air FranceKLM
EU
BEL20
Bel 20
NYSE
NKE
Nike
EU
VK
Vallourec
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés